Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2022 Earnings Presentation

59 slides from Aspen Pharmacare's earnings presentation, March 2022

  1. Slide 1: Interim Results Presentation

    Interim Results Presentation For the six months ended 31 December 2021

  2. Slide 2: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S.

  3. Slide 3: Disclosure Note

    DISCLOSURE NOTE RESTATEMENT OF THE GROUP SEGMENTAL ANALYSIS  The Group has revised its reportable segments to reflect the newly updated operating model which aligns to the way in which the business is managed and reported on by the Chief Operating Decision Maker (“CODM”).  The business segments wh

  4. Slide 4: Financial Review

    Financial Review

  5. Slide 5: Group CFO Insights

    GROUP CFO INSIGHTS SALES EBITDA EARNINGS 5

  6. Slide 6: Group CFO Insights

    GROUP CFO INSIGHTS Aspen is in Delivering on our Improved gross good shape and lean organic sales growth margins (CERⱡ) despite targets (CERⱡ) challenging headwinds • Sales (CERⱡ) ↑ 10% and Expenses • Commercial Pharma ↑ 5% • Commercial Pharma ↑ 58.5% ↓ 2% (CERⱡ) - strong levers for • Manufacturing

  7. Slide 7: Group CFO Insights

    GROUP CFO INSIGHTS Manufacturing Double digit segment endured a Improved return on EBITDA and challenging H1 2022 with investment NHEPS Growth (CERⱡ) recovery expected in H2 2022 • EBITDA ↑ 15% • Increased ROIC trend • COVID impacted costs, efficiencies • NHEPS ↑ 26% • EBITDA margin 29.5% - highest

  8. Slide 8: Group CFO Insights

    GROUP CFO INSIGHTS Increased inventory investment in Manufacturing Increased to ensure sustainable inventory investment Exciting supply to Commercial Strong balance sheet to to ensure sustainable developments enhance support growth supplymarkets to Commercial future prospects markets • Stock-piling

  9. Slide 9: Financial Highlights

    FINANCIAL HIGHLIGHTS CONTINUING +10% CERⱡ +15% CERⱡ +26% CERⱡ Revenue Normalised EBITDA Normalised EBITDA Normalised Headline Net Borrowings# Margin % Earnings ⱡ CER removes the currency effect on performance. H1 2021 has been restated at H1 2022 average exchange rates. # Current borrowings + non-cu

  10. Slide 10: Currency Mix

    CURRENCY MIX H1 2022 FY 2021 H1 2022 H1 2021 Currency contribution Normalised Normalised % change Revenue Revenue average rate average rate EBITDA EBITDA EUR 29% 14% 29% 17% 17.44 19.19 (9%) ZAR 17% 10% 18% 16% AUD 14% 21% 13% 21% 10.99 11.75 (6%) CNY 10% 22% 10% 23% 2.34 2.40 (3%) USD 7% (13%) 7% (

  11. Slide 11: Normalised EBITDA

    NORMALISED EBITDA CONTINUING R'million H1 2022 % of revenue H1 2021 % of revenue % change % change CERⱡ Revenue 19 381 100.0% 18 633 100.0% 4% 10% Gross profitⴃ 9 395 48.5% 9 186 49.3% 2% 7% Depreciation 582 3.0% 511 2.7% 14% 20% Operating expenses (4 287) 22.1% (4 605) 24.7% -7% -2% Net other opera

  12. Slide 12: Gross Profit Percentage CER

    GROSS PROFIT PERCENTAGE CERⱡ CONTINUING Regional Brands Sterile Focus Brands 56.0% 54.4% 56.9% 60.1% 59.4% 59.7% 61.0% Favourable higher 52.9% Higher Anaesthetic margin sales mix in margins outweighed Africa Middle East and reduced Thrombosis Americas coupled with margins supply cost savings H1 2021

  13. Slide 13: Effective Tax Rates

    EFFECTIVE TAX RATES CONTINUING 19.9% 19.9% 19.5% 19.3% 17.7% 16.8% 16.9% 16.4% FY 2020 H1 2021 FY 2021 H1 2022 Group effective tax rate Group normalised effective tax rate  Increased contribution mix from Manufacturing increases H1 2022 Group tax rates  It is anticipated that the FY 2022 Group nor

  14. Slide 14: Normalised Headline Earnings Bridge

    NORMALISED HEADLINE EARNINGS BRIDGE CONTINUING R’MILLION +21% +26% -221 288 3 728 -98 34 758 3 086 -119 2 967 Normalised FX Normalised Normalised Depreciation Amortisation Net financing Tax Normalised Headline Headline EBITDA cost Headline Earnings Earnings CERⱡ Earnings Reported 31 Dec 2020 31 Dec

  15. Slide 15: Working Capital

    WORKING CAPITAL Net working capital % of revenue^ Net working capital by segment % 63% Manufacturing 44% 45% 37% Commercial Pharma 37% R17 351 million 38% Total 35% Excluding Oss 31% H1 2021 FY 2021 H1 2022 Net working capital  Net working capital ("NWC") ratios are marginally up R’million H1 2022

  16. Slide 16: Operating Cash Flow

    OPERATING CASH FLOW CONTINUING AND DISCONTINUED Operating cash conversion cycle R'million H1 2022 H1 2021 % change 200% Cash operating profit 5 263 4 823 9% 150% Changes in working capital (2 301) (1 411) 63% Cash generated from operations 2 962 3 412 -13% 100% Net finance costs paid ( 290) ( 665) -

  17. Slide 17: Capital Expenditure

    CAPITAL EXPENDITURE PPE capexˠ in R’million PPE CAPEXˠ 2 400  Low H1 2022 spend impacted by COVID related delays. 2 300 2 039 2 045 Underspend will carry forward to H2 2022 800  FY 2022 includes capex for the rehabilitation of the Alphamed site in India and initial vaccine capacity expansion capex

  18. Slide 18: Borrowings

    BORROWINGS Net borrowings» in R’million 35 228 6 302 27 682 8 216 19 310 16 326 7 274  Leverage ratio* well below Group ceiling of 3.0x and covenant level of 3.5x 36 019  Oss loan owing to MSD of EUR 188 million due in September 2023 is 29 259 24 606 19 912 excluded from Net Borrowings 266  The m

  19. Slide 19: Financial Highlights Summary

    FINANCIAL HIGHLIGHTS SUMMARY IMPROVED GROSS DOUBLE DIGIT DELIVERING ON OUR ASPEN IS IN MARGINS (CERⱡ) EBITDA AND ORGANIC SALES GOOD SHAPE AND DESPITE NHEPS GROWTH GROWTH TARGETS LEAN CHALLENGING (CERⱡ) (CERⱡ) HEADWINDS INCREASED MANUFACTURING INVENTORY SEGMENT ENDURED INVESTMENT TO EXCITING A CHALLE

  20. Slide 20: Performance Review

    S a > wo [aa wo [8] Cc © & pa fe) _— — )) a Healthcare. We Care.

  21. Slide 21: Performance

    PERFORMANCE A SUCCESSFUL STORY OF ORGANIC GROWTH, CARE, HOPE AND FUTURE OPPORTUNITIES Double Strengthened Forefront of Aspenovax digit growth the balance equitable access Caring for sheet Africa Business Organic growth Critical global Contribution to Capacities are reshaped across all capacities wor

  22. Slide 22: ESG | Delivering the Big Capital S in ESG

    ESG | DELIVERING THE BIG CAPITAL S IN ESG Next? ASPEN FOR AFRICA Vaccines, insulin, oncology, pain, anaesthetics Realisation of 180m COVID doses African ambition Over 1 000 000 for Africa HIV/ AIDS patients reached in Africa MDR TB Ensuring manufacturing capabilities are relevant for First FDA Aspen

  23. Slide 23: Group Revenue

    GROUP REVENUE CONTINUING % change R'million H1 2022 H1 2021 Reported CERⱡ Commercial Pharma 14 261 14 331 0% 5% ORGANIC GROWTH Regional Brands 8 727 8 776 -1% 4% ACROSS ALL SEGMENTS Sterile Focus Brands 5 534 5 555 0% 5% Manufacturing 5 120 4 302 19% 30% Group revenue 19 381 18 633 4% 10%  Another

  24. Slide 24: Commercial Pharma | Regional Brands

    COMMERCIAL PHARMA | REGIONAL BRANDS CONTINUING | REVENUE % change R’million H1 2022 H1 2021 Reported CERⱡ Africa Middle East 3 961 4 059 -2% 0% Australasia 2 303 2 082 11% 18% ANOTHER RESILIENT PERFORMANCE LED Americas 1 361 1 329 2% 8% BY AUSTRALIA Europe CIS 803 970 -17% -10% Asia 299 336 -11% -4%

  25. Slide 25: Commercial Pharma | Steriles

    COMMERCIAL PHARMA | STERILES CONTINUING | REVENUE % change R’million H1 2022 H1 2021 Reported CERⱡ Asia 2 426 2 262 7% 11% Europe CIS 1 795 1 892 -5% 3% MAINTAINING Americas 718 736 -2% 2% STRONG MOMENTUM Australasia 353 397 -11% -5% Africa Middle East 242 268 -10% -4% Sterile Focus Brands 5 534 5 5

  26. Slide 26: Manufacturing Revenue

    MANUFACTURING REVENUE CONTINUING | REVENUE % change R’million H1 2022 H1 2021 Reported CERⱡ FDF 2 476 1 051 >100% >100% COVID VACCINE API - Chem 2 206 2 708 -19% -11% POSITIVE IMPACT API - Biochem 438 543 -19% -11% Manufacturing 5 120 4 302 19% 30%  Extremely challenging times to be in production »

  27. Slide 27: Aspen Strategy

    ASPEN STRATEGY CONSISTENT WITH DECEMBER 2020 INVESTOR GUIDANCE Sterile build steppingstone Improving to growth financial strategy Acquisitive metrics opportunities Capacity fill Organic growth of base business 27

  28. Slide 28: Performance Metrics: Organic Growth of Base Business

    PERFORMANCE METRICS CER ORGANIC GROWTH OF 3 – 7% OF BASE BUSINESS* ORGANIC GROWTH IS THE CORE FOCUS FOR THE ASPEN TEAM  Base business is the cash generator and growth engine  Performance in spite of COVID disruptions Organic Growth Performance  Sustained growth of base » Innovative, evolving stra

  29. Slide 29: Performance Metrics: Australian Base Business

    PERFORMANCE METRICS ORGANIC GROWTH - OUR BRANDED AUSTRALIAN BASE BUSINESS OUR OTC / OTX PORTFOLIO HAS GROWN AT 19% MARKET LEADER IN 6 OTC / OTX CATEGORIES  Now represents 40% of Regional Brands revenue in  Maltofer - Iron deficiency (Oral) Australia  Ural - UTI management  Not impacted by price

  30. Slide 30: Performance Metrics: SA Base Business

    PERFORMANCE METRICS ORGANIC GROWTH - OUR BRANDED SA BASE BUSINESS OUR SA OTC / OTX BUSINESS HAS GROWN AT 25% NON-NARCOTIC ANALGESICS ANTI-SPASMODICS PRESCRIBED IRON TREATMENT  Largest OTC class in SA private market  Hyospasmol - leading brand in this  Ferrimed is the market leader » Aspen share o

  31. Slide 31: Performance Metrics: Capacity Fill and Anaesthetic Savings

    PERFORMANCE METRICS CAPACITY FILL AND ANAESTHETIC SAVINGS EBITDA CONTRIBUTION OF R2.3 BILLION BY 2024 ON TARGET WITH AT LEAST 50% BY FY 2022 NDB absentee rate  R2.3 billion contribution 160 » R1.5 billion contribution from half of available capacity fill » R0.8 billion Anaesthetic savings 140  Com

  32. Slide 32: Performance Metrics: Acquisitions

    PERFORMANCE METRICS ACQUISITIONS FOCUS OVER LAST FEW PERIODS HAS BEEN ON RESHAPE AND ASPENOVAX  Commercial pharmaceutical portfolios largely completed ANTICIPATE ACQUISITIVE ACTIVITY  Targeting acquisitions of brands » Expand portfolios across existing geographic footprint » Focus areas include •

  33. Slide 33: Performance Metrics: COVID Challenges

    PERFORMANCE METRICS COVID CHALLENGES SA OPERATIONS WERE MORE OUR THIRD-PARTY STRONG PERFORMANCE, COVID SUPPLY RELATED IMPACTED BY THE OMICRON SUPPLIERS SIMILARLY DESPITE PRESSURES IMPACTS WAVE IMPACTED  Supply, productivity and cost  Shortages of key ingredients  SA specific isolation and flights

  34. Slide 34: Performance Metrics: COVID Challenges

    PERFORMANCE METRICS COVID CHALLENGES COVID IMPACT TO PRODUCTIVITY HAS PRICING CHALLENGES THESE CHALLENGES PERSIST TODAY BEEN PROFOUND  Absenteeism high and entire shifts  Freight and transport costs have  Duration hard to predict cancelled increased exponentially  Much may depend on severity and

  35. Slide 35: Financial Metrics

    FINANCIAL METRICS PERFORMING AGAINST ALL METRICS FINANCIAL METRICS ON TRACK  Successful implementation of strategy » Improving return metrics TARGET ACHIEVED  Increase off base FY 2020 EBITDA margin of 25.8%  29.5% EBITDA margin  EBITDA growth > Revenue growth  EBITDA growth of 15% > Revenue gr

  36. Slide 36: Prospects

    ASPeNn Healthcare. We Care. Prospects

  37. Slide 37: Prospects: Sterile Capacity

    PROSPECTS STERILE CAPACITY | A RELEVANT AND VALUABLE STRATEGIC CAPABILITY Sterile demand continues to increase COVID has catapulted Aspen's African sterile manufacture onto the global stage  New chemical entity developments are largely sterile based  The South African facility is focused on the CO

  38. Slide 38: Prospects: Headwinds to Organic Growth

    PROSPECTS BASE BUSINESS | HEADWINDS TO ORGANIC GROWTH COVID CHALLENGES HAVE BEEN  These remain today SIGNIFICANT » Manufacturing, supply, logistics and related inflationary pressures DIRECT AND KNOCK-ON RISKS OF  Annualized sales about R1 billion, mainly in Russia RUSSIA/ UKRAINE HOSTILITIES  Fur

  39. Slide 39: Prospects: Tailwinds to Organic Growth

    PROSPECTS BASE BUSINESS | TAILWINDS TO ORGANIC GROWTH OUR BASE BUSINESS ENJOYED  Relevant product range in growing markets SUSTAINED POSITIVE MOMENTUM  Improving margin profiles ASPENOVAX TO DRIVE A MATERIAL INCOME STREAM FOR ASPEN  Our contribution to our continent WE HAVE A ROBUST PIPELINE TO 

  40. Slide 40: Prospects: Vaccine Inequity

    PROSPECTS VACCINE INEQUITY - REGIONAL MANUFACTURE HAS TO BE AN AFRICAN IMPERATIVE More than 10 billion doses administered globally, but inequities persist 10.4 billion vaccine doses administered globally as of Feb 25th, 2022 3.4 billion vaccine doses administered across participants Strong global va

  41. Slide 41: Prospects: The Road to Aspenovax

    PROSPECTS Aspenovax agreement THE ROAD TO ASPENOVAX concluded March 2022 Aspen to launch Johnson & Johnson Aspenovax circa commitment to June 2022 enabling a solution to COVID supply in Africa Aspen vision for own COVID vaccine brand for Africa Aspen recognised as top contributor to Johnson & Johnso

  42. Slide 42: Prospects: Aspenovax Potential Financial Outcomes

    PROSPECTS ASPENOVAX – POTENTIAL FINANCIAL OUTCOMES VARIABLES RELEVANT FACTORS  Volumes ordered  AVAT, COVAX, African Governments will be principal customers  Selling price per dose  Vaccine pricing currently USD 5-10 per dose  Cost of Goods per dose  Formula based and heavily influenced by man

  43. Slide 43: Prospects: Aspenovax as Enabler

    PROSPECTS ASPENOVAX AS ENABLER Alignment to our purpose to improve the health and quality of life for patients Potential for improving returns from Aspenovax – commitment to reinvest in increasing capacity in Africa and a broader vaccine pipeline Stimulated interest in partnering Aspen to enhance ac

  44. Slide 44: Prospects: Summary

    PROSPECTS SUMMARY CHALLENGING BUT REWARDING PERIOD OPERATIONALLY RESHAPING DELIVERING MEANINGFUL RETURNS • Better positioned Aspen business strategically • Durable branded products – resilient margins • Leading global sterile manufacturing platform » Inspired investment ahead of the curve » Foundati

  45. Slide 45: Prospects: Summary

    PROSPECTS SUMMARY OUR COMMERCIAL PHARMACEUTICAL BUSINESS HAS OUR MANUFACTURING OPERATIONS EXPECTED TO PERFORMED WELL HAVE A MUCH STRONGER H2 • H2 vs H1 will have a revenue adjustment of R500m for divested • Aspenovax could also contribute to this half products in SA and Naropin VBP • Geopolitical te

  46. Slide 46: Appendices

    Appendices

  47. Slide 47: Appendix 1: ESG - Focusing Our Efforts Where It Matters

    APPENDIX 1 : ESG - FOCUSING OUR EFFORTS WHERE IT MATTERS  Initiated development of Climate Change strategy and related roadmaps and targets ESG CREDENTIALS  Mitigation of electricity and water availability risks at SA Operations  No significant environmental incidents UN Global Compact signatory

  48. Slide 48: Appendix 2: Strategic Positioning

    APPENDIX 2: STRATEGIC POSITIONING BRANDED, SPECIALTY COMPLEX MANUFACTURING EXTENSIVE COMMERCIAL PRODUCT PORTFOLIO CAPABILITIES FOOTPRINT Sterile & Regional FDF & API Covering more than 50 countries Ongoing portfolio renewal through Leverage of installed capacity creates Delivering predictable annuit

  49. Slide 49: Appendix 3: Strong Fundamentals for Organic Growth

    APPENDIX 3: STRONG FUNDAMENTALS FOR ORGANIC GROWTH RESHAPED ASPEN’S ENHANCED COMMERCIAL ORGANIC MANUFACTURING PHARMA GROWTH CAPACITIES MODEL DRIVERS & CAPABILITIES Commercial Pharma Fundamentals Manufacturing Fundamentals Focussed on territories with strong demographic growth Increasing demand for q

  50. Slide 50: Appendix 4: Abridged Statement of Comprehensive Income

    APPENDIX 4: ABRIDGED STATEMENT OF COMPREHENSIVE INCOME CONTINUING AND DISCONTINUED R’million H1 2022 H1 2021 % change FY 2021 Net revenue 19 381 20 545 -6% 39 705 Cost of sales (9 986) (10 870) (21 515) Gross profit 9 395 9 675 -3% 18 190 Gross profit margin 48.5% 47.1% 45.8% Operating expenses (4 2

  51. Slide 51: Appendix 5: Abridged Statement of Normalised Comprehensive Income

    APPENDIX 5: ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME CONTINUING R’million H1 2022 H1 2021 % change H1 2021 (CERⱡ) % change (CERⱡ) FY 2021 Net revenue 19 381 18 633 4% 17 581 10% 37 766 Cost of sales (9 986) (9 447) 6% (8 825) 13% (19 977) Gross profit 9 395 9 186 2% 8 756 7% 17 789 Gros

  52. Slide 52: Appendix 6: Net Financing Costs

    APPENDIX 6: NET FINANCING COSTS CONTINUING R’million H1 2022 H1 2021 FY 2021 Net interest paid (291) (460) (854) Foreign exchange gain/ (losses) 50 (104) (49) Notional interest on financial instruments (93) (103) (211) Normalised net funding costs (334) (667) (1 114) Debt raising fees on acquisition

  53. Slide 53: Appendix 7: Reconciliation of NHEPS

    APPENDIX 7: RECONCILIATION OF NHEPS CONTINUING AND DISCONTINUED Cents H1 2022 H1 2021 % change H1 2021 (CERⱡ) % change (CERⱡ) FY 2021 Basic earnings per share (EPS) 736.2 558.4 32% 537.8 37% 1 052.9 Impairment of property, plant and equipment 0.3 0.3 0.3 29.1 Impairment of intangible assets 77.2 63.

  54. Slide 54: Appendix 8: Reconciliation of NHEPS

    APPENDIX 8: RECONCILIATION OF NHEPS CONTINUING Cents H1 2022 H1 2021 % change H1 2021 (CERⱡ) % change (CERⱡ) FY 2021 Basic earnings per share (EPS) 736.2 498.8 48% 483.6 52% 1 051.1 Impairment of property, plant and equipment 0.3 0.3 0.3 29.1 Impairment of intangible assets 77.2 63.5 57.7 274.8 Insu

  55. Slide 55: Appendix 9.1: Group Statement of Financial Position

    APPENDIX 9.1: GROUP STATEMENT OF FINANCIAL POSITION R'million H1 2022 H1 2021 FY 2021 TOTAL ASSETS Non-current assets 80 828 80 760 76 979 Intangible assets 57 723 58 101 54 882 Property, plant and equipment 15 528 14 336 14 826 Right-of-use assets 385 487 400 Goodwill 4 943 4 923 4 621 Deferred tax

  56. Slide 56: Appendix 9.2: Group Statement of Financial Position

    APPENDIX 9.2: GROUP STATEMENT OF FINANCIAL POSITION R‘million H1 2022 H1 2021 FY 2021 EQUITY AND LIABILIITIES Shareholders equity 71 961 66 354 65 627 Non-current liabilities 26 760 37 770 7 306 Borrowings 19 912 29 259 266 Other non-current liabilities 3 546 4 419 3 732 Unfavourable and onerous con

  57. Slide 57: Appendix 10: Gross Profit Percentage Bridge CER

    APPENDIX 10: GROSS PROFIT PERCENTAGE BRIDGE CERⱡ CONTINUING -0.8% -1.3% 0.5% 0.3% 49.8% -1.7% Increase in Commercial 0.5% Pharmaceuticals (+0.8%) 49.3% 0.5% -0.9% Decrease in Manufacturing (-1.2%) 48.5% Gross profit FX Gross profit Sterile Focus Regional Brands FDF TRS* Manufacturing Segmental mix G

  58. Slide 58: Appendix 11: Net Working Capital Bridge CER

    APPENDIX 11 : NET WORKING CAPITAL BRIDGE CERⱡ R’MILLION 17 351 -225 274 1 266 1 260 1 093 Manufacturing 14 775 167 Commercial Pharma 804 13 971 Cash Outflow (2 301) Net Working Fx impact Net Working Inventory Receivables Payables Non cash Net Working Capital FX Capital Capital Reported CERⱡ 31 Dec 2

  59. Slide 59: Appendix 12: Net Borrowings Bridge

    APPENDIX 12 : NET BORROWINGS BRIDGE R’MILLION 19 310 77 1 195 1 298 -1 761 17 240 1 130 914 131 16 326 South Africa - ZAR 23% International - EUR 69% Net Borrowings FX Net Borrowings Larger acquisitions Cashflows from Bolt-on acquisitions Capex (IP Dividends Other Net Borrowings 30 Jun 2021 CERⱡ 30

Aspen Pharmacare Holdings — H1 2022 Earnings Presentation on 6ix